Clinical TrialsSearch results
Number of results: 566
Recruiting
- Phase II study of VAC1.2/VI therapy for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.
- rhabdomyosarcoma
- Miyachi Mitsuru
- 2019-03-26
Other
- Clinical trial of TK-98 on retinitis pigmentosa: A prospective, randomized, double-blind, placebo-controlled study
- retinitis pigmentosa
- Ikeda Hanako
- 2019-02-22
Other
- A Multicenter Randomized Controlled Trial to Evaluate the Effect of Adjuvant Chemotherapy using Gemcitabine After Resection of Pancreatic Cancer
- resectable pancreatic cancer
- Study Group for Adjuvant Chemotherapy of Pancreatic Cancer
- 2005-08-05
Other
- RCC-SNPs Ensuring-study for Leading Eligibility of patients in Cytokine Therapy
- Renal cell carcinoma
- JISG-KC
- 2007-06-04
Other
- Multi-institute randomized study of natural type interferon alpha for patients with renal cell carcinoma after radical nephrectomy
- Renal cell carcinoma
- TRAIn-Alpha study group
- 2005-09-30
Other
- Multi-Center Phase II Study on Efficacy of High-Slip Skin Care Pad for Hand-Foot Skin Reaction Caused by Sorafenib in Patients with Renal Cell Carcinoma
- Renal cell carcinoma
- Japanese Society of Renal Cancer (JSRC)
- 2009-05-29
Other
- Phase II Study of Docetaxel and TS-1 Combination Therapy for Outpatients with Relapsed or Refractory Non-small Cell Lung cancer
- Relapsed or Refractory Non-small Cell Lung Cancer
- Outpatient Oncology Unit Kyoto University Hospital
- 2006-10-12
Recruiting
- A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IberDd) VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) (EXCALIBER-RRMM)
- Relapsed or refractory multiple myeloma (RRMM)
- Kimura Shunsuke
- 2021-07-01
Recruiting
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination with Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Relapsed or Refractory Multiple Myeloma
- Nishikawa Kazuko
- 2022-10-07
Recruiting
- A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects with Relapsed and Refractory Multiple Myeloma
- Relapsed and refractory multiple myeloma
- Hayakawa Jin
- 2023-10-04